Nippon Chemiphar Revises FY2026 Forecast on Pharma Timing Shifts

Nippon Chemiphar Revises FY2026 Forecast on Pharma Timing Shifts

Nippon Chemiphar Co., Ltd. (TSE:4539) has revised its earnings forecast for the fiscal year ending March 2026, citing timing adjustments in core pharmaceutical product sales that will pressure operating profit despite a currency-driven boost to ordinary income.

The company expects revenue to decline 1.2% to JPY 33.1bn, driven by timing adjustments in sales of flagship and new pharmaceutical products. Operating profit is forecast to fall 40.3% to JPY 179M as a result. However, ordinary income (keijo rieki)—a Japan-specific metric capturing non-operating items—is projected to surge 127% to JPY 227M, buoyed by foreign exchange gains on the company’s foreign currency-denominated assets and liabilities. Additionally, the company will record a JPY 163M special loss related to investment securities valuation adjustments.

The net effect is a 32% increase in net profit attributable to parent shareholders to JPY 198M, with earnings per share rising to JPY 54.81/share from JPY 41.51/share. International investors should note that the divergence between operating profit and ordinary income reflects significant non-operating financial gains—primarily currency-related—rather than operational strength. The pharmaceutical sales timing shift signals near-term headwinds in core business performance, though the bottom-line profit improvement masks this underlying weakness. Investors should monitor whether the timing adjustments represent a temporary dislocation or signal broader demand challenges in the company’s key product portfolio.

Source: Original filing (TDnet) | 日本語版

This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.